BioPharmSignal logoBioPharmSignal

Biotech News

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

RxSight (RXST)RxSightPartnership

Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies Collaboration aims to combine best-in-class PCIOL optics with first-in-class platform to enable fine-tuning of visual outcomes after cataract surgery ALISO VIEJO,

Related news

RXSTRxSight2026-07-06 20:15 EST

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

RXSTRxSight2026-08-05 20:05 EST

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

VTAKCatheter Precision2026-07-29 13:15 EST

Flyte Partners with LDV at The Maidstone to Elevate Luxury Travel to the Hamptons

VTAKCatheter Precision2026-07-27 12:00 EST

FLYTE Partners with 319 Golf Society and Named Exclusive Private Aviation Partner

ATRCAtriCure2026-07-02 12:00 EST

AtriCure to Announce Second Quarter 2026 Financial Results

TCMDTactile Systems Technology, Inc.2026-07-13 12:00 EST

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

SENSSenseonics2026-06-10 12:00 EST

Senseonics and Welldoc Partner to Develop Next-Generation App for Eversense® 365

View all latest news

RxSight

Adjustable Cataract Lenses RxSight is an ophthalmic medical-device company focused on customized vision after cataract surgery. Light Adjustable Lens System The system combines an implantable Light Adjustable Lens with a Light Delivery Device. After surgery, physicians use ultraviolet light treatments to modify the lens and refine the...

Recent company news

RXSTRxSight2026-08-05 20:05 EST

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RXSTRxSight2026-07-26 20:00 EST

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

RXSTRxSight2026-07-15 20:15 EST

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RXSTRxSight2026-07-06 20:16 EST

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

RXSTRxSight2026-07-06 20:15 EST

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

Stock data

Close
6.08 USD
Market cap
204.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States